Add Glucokinase Activator to Target A1c

A phase 2 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 190 participants.

Also called NCT02405260

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; double masking; primary purpose treatment
Phase
Phase 2
Enrolled
  • 190 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT02405260
Start date
(registry gives no type) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Countries
United States (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT02405260. Randomized; double masking; primary purpose treatment. Start 2015-03 (registry gives no type); primary completion 2016-07 (actual). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Add Glucokinase Activator to Target A1c
Acronym
AGATA
Condition
Diabetes Mellitus, Type 2
Intervention (Drug)
TTP399 400 mg
Intervention (Drug)
TTP399 800 mg
Intervention (Drug)
Sitagliptin 100 mg
Intervention (Drug)
Placebo
Lead sponsor
vTv Therapeutics (class: industry)

Record details

Record id
cardio:ct-nct02405260
Content hash
9f4b1202b80f5b5506c287dc099ee69801031eb3ed6a7ce11701617d7fcd6f05